search

Active clinical trials for "Crohn Disease"

Results 181-190 of 1510

A Study of Darvadstrocel in Adults With Crohn's Disease and Complex Perianal Fistula

Crohn's DiseaseComplex Perianal Fistula

The main aim is to check the long term side effects of a repeat treatment of darvadstrocel and to see if that treatment improves symptoms of Crohn's disease and complex perianal fistula. Participants will attend 8 clinic visits and will receive 1 treatment of darvadstrocel at the third visit. A magnetic resonance imaging (MRI) will be performed several times during the study.

Active38 enrollment criteria

A Study of E6011 in Participants With Active Crohn's Disease

Crohn's Disease

The primary purpose of this study is to examine the efficacy and safety of E6011 at 12 weeks after administration by means of double-blind placebo-controlled trial.

Active13 enrollment criteria

A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's...

Crohn Disease

The purpose of this study is to evaluate the efficacy and safety of guselkumab in participants with Crohn's disease.

Active6 enrollment criteria

Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change...

Crohn's Disease (CD)

Crohn's disease (CD) is a long-lasting condition causing inflammation that can affect any part of the gut. This study will evaluate how well risankizumab works compared to ustekinumab. This study will assess change in Crohn's Disease Activity Index (CDAI). Risankizumab is an investigational drug being developed for the treatment of Crohn's Disease (CD). Ustekinumab is an approved drug for the treatment of moderate and severe CD. Participants are randomly assigned to one of the three treatment groups. Each group receives a different treatment. There is a 1 in 2 chance that participants will be assigned to ustekinumab. Around 508 adult participants with moderate to severe CD will be enrolled in approximately 307 sites worldwide. In Part 1, participants assigned to risankizumab will receive intravenous (IV) doses of risankizumab at Week 0, 4,8 and subcutaneous (SC) doses every 8 weeks thereafter through Week 48. Participants assigned to ustekinumab will receive intravenous (IV) dose of ustekinumab at Week 0 and subcutaneous (SC) doses every 8 weeks thereafter through Week 48. In Part 2, participants who received risankizumab in Part 1 and completed the Week 48 visit will continue to receive SC risankizumab for up to an additional 220 weeks. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Active8 enrollment criteria

Autologous Unselected Hematopoietic Stem Cell Transplantation for Refractory Crohn's Disease

Crohn's DiseaseInflammatory Bowel Diseases1 more

This study evaluates the safety and clinical benefits of a therapeutic approach using the cyclophosphamide (Cy) + thymoglobulin® (ATG) + granulocyte colony-stimulating factor (G-CSF) conditioning regimen followed by autologous hematopoietic stem cell transplantation (HSCT) rescue in the treatment of refractory Crohn's disease. Adverse events, and clinical and endoscopic conditions will be assessed at different short and long-term time points.

Active23 enrollment criteria

Changing the coUrse of cRohn's Disease With an Early Use of Adalimumab

CD

This is a prospective, longitudinal, multicenter study conducted in a cohort of patients with early CD. This study will not change the patient/physician relationship.

Active14 enrollment criteria

A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active...

Crohn's Disease

The purpose of this study is to evaluate the clinical efficacy (GALAXI 1), clinical and endoscopic efficacy (GALAXI 2 and GALAXI 3) and safety of guselkumab in participants with Crohn's disease.

Active10 enrollment criteria

A Phase I Study Of Etrolizumab Followed By Open-Label Extension And Safety Monitoring In Pediatric...

Ulcerative ColitisCrohn's Disease

This study will evaluate pharmacokinetics, pharmacodynamics and safety of etrolizumab in pediatric patients of 4 to <18 years of age with moderate to severe ulcerative colitis (UC) or with moderate to severe Crohn's disease (CD).

Active36 enrollment criteria

Induction Study #2 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's...

Crohn Disease

This is a study to explore the effect of oral ozanimod as an induction treatment for participants with moderately to severely active Crohn's Disease.

Active10 enrollment criteria

A Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

Crohn's Disease

The reason for this study is to see if the study drug mirikizumab is safe and effective in participants with moderately to severely active Crohn's disease.

Active9 enrollment criteria
1...181920...151

Need Help? Contact our team!


We'll reach out to this number within 24 hrs